Literature DB >> 31708112

Overexpression of neuropeptide Y decreases responsiveness to neuropeptide Y.

Katelynn M Corder1, Qin Li2, Mariana A Cortes2, Aundrea F Bartley2, Taylor R Davis2, Lynn E Dobrunz3.   

Abstract

Neuropeptide Y (NPY) is an endogenous neuropeptide that is abundantly expressed in the central nervous system. NPY is involved in various neurological processes and neuropsychiatric disorders, including fear learning and anxiety disorders. Reduced levels of NPY are reported in Post-Traumatic Stress Disorder (PTSD) patients, and NPY has been proposed as a potential therapeutic target for PTSD. It is therefore important to understand the effects of chronic enhancement of NPY on anxiety and fear learning. Previous studies have shown that acute elevation of NPY reduces anxiety, fear learning and locomotor activity. Models of chronic NPY overexpression have produced mixed results, possibly caused by ectopic NPY expression. NPY is expressed primarily by a subset of GABAergic interneurons, providing specific spatiotemporal release patterns. Administration of exogenous NPY throughout the brain, or overexpression in cells that do not normally release NPY, can have detrimental side effects, including memory impairment. In order to determine the effects of boosting NPY only in the cells that normally release it, we utilized a transgenic mouse line that overexpresses NPY only in NPY+ cells. We tested for effects on anxiety related behaviors in adolescent mice, an age with high incidence of anxiety disorders in humans. Surprisingly, we did not observe the expected reduction in anxiety-like behavior in NPY overexpression mice. There was no change in fear learning behavior, although there was a deficit in nest building. The effect of exogenous NPY on synaptic transmission in acute hippocampal slices was also diminished, indicating that the function of NPY receptors is impaired. Reduced NPY receptor function could contribute to the unexpected behavioral outcomes. We conclude that overexpression of NPY, even in cells that normally express it, can lead to reduced responsiveness of NPY receptors, potentially affecting the ability of NPY to function as a long-term therapeutic.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31708112      PMCID: PMC6960342          DOI: 10.1016/j.npep.2019.101979

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  82 in total

Review 1.  Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V.

Authors:  Katja Beesdo; Susanne Knappe; Daniel S Pine
Journal:  Psychiatr Clin North Am       Date:  2009-09

2.  Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models.

Authors:  M Heilig; B Söderpalm; J A Engel; E Widerlöv
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Transcriptional dysregulation causes altered modulation of inhibition by haloperidol.

Authors:  Lillian J Brady; Aundrea F Bartley; Qin Li; Laura J McMeekin; John J Hablitz; Rita M Cowell; Lynn E Dobrunz
Journal:  Neuropharmacology       Date:  2016-07-29       Impact factor: 5.250

4.  Modulation of neuropeptide Y expression in adult mice does not affect feeding.

Authors:  Linda Ste Marie; Serge Luquet; Toby B Cole; Richard D Palmiter
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-08       Impact factor: 11.205

Review 5.  Thinking outside the pyramidal cell: unexplored contributions of interneurons and neuropeptide Y to estrogen-induced synapse formation in the hippocampus.

Authors:  Nozomu H Nakamura; Keith T Akama; Genevieve S Yuen; Bruce S Mcewen
Journal:  Rev Neurosci       Date:  2007       Impact factor: 4.353

6.  Endogenously Released Neuropeptide Y Suppresses Hippocampal Short-Term Facilitation and Is Impaired by Stress-Induced Anxiety.

Authors:  Qin Li; Aundrea F Bartley; Lynn E Dobrunz
Journal:  J Neurosci       Date:  2017-01-04       Impact factor: 6.167

7.  Anxiolytic-like actions of centrally-administered neuropeptide Y, but not galanin, in C57BL/6J mice.

Authors:  Rose-Marie Karlsson; Andrew Holmes; Markus Heilig; Jacqueline N Crawley
Journal:  Pharmacol Biochem Behav       Date:  2005-01-25       Impact factor: 3.533

8.  Single intranasal neuropeptide Y infusion attenuates development of PTSD-like symptoms to traumatic stress in rats.

Authors:  L I Serova; A Tillinger; L G Alaluf; M Laukova; K Keegan; E L Sabban
Journal:  Neuroscience       Date:  2013-01-30       Impact factor: 3.590

9.  Blockade of neuropeptide Y(2) receptors and suppression of NPY's anti-epileptic actions in the rat hippocampal slice by BIIE0246.

Authors:  Bouchaïb El Bahh; Jeffrey Q Cao; Annette G Beck-Sickinger; William F Colmers
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

10.  NPY gene transfer in the hippocampus attenuates synaptic plasticity and learning.

Authors:  Andreas T Sørensen; Irene Kanter-Schlifke; Mirjana Carli; Claudia Balducci; Francesco Noe; Matthew J During; Annamaria Vezzani; Merab Kokaia
Journal:  Hippocampus       Date:  2008       Impact factor: 3.899

View more
  3 in total

1.  Neuropeptide Y and Peptide YY in Association with Depressive Symptoms and Eating Behaviours in Adolescents across the Weight Spectrum: From Anorexia Nervosa to Obesity.

Authors:  Marta Tyszkiewicz-Nwafor; Katarzyna Jowik; Agata Dutkiewicz; Agata Krasinska; Natalia Pytlinska; Monika Dmitrzak-Weglarz; Marta Suminska; Agata Pruciak; Bogda Skowronska; Agnieszka Slopien
Journal:  Nutrients       Date:  2021-02-11       Impact factor: 5.717

Review 2.  Current Insights Into the Role of Neuropeptide Y in Skin Physiology and Pathology.

Authors:  Zoya T Anderson; Alex D Dawson; Andrzej T Slominski; Melissa L Harris
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-28       Impact factor: 5.555

Review 3.  Neuropeptide Y Is an Immunomodulatory Factor: Direct and Indirect.

Authors:  Wei-Can Chen; Yi-Bin Liu; Wei-Feng Liu; Ying-Ying Zhou; He-Fan He; Shu Lin
Journal:  Front Immunol       Date:  2020-10-06       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.